20th August 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

"Impossible, " says Dolo 650 manufacturer in response to allegations of Rs 1000 crore marketing budget

Micro Labs Limited, based in Bengaluru, dismissed allegations that it had given freebies worth Rs 1000 crore to doctors in order to promote its Dolo-650 tablets as “baseless and incorrect” on Friday.

GSK secures $170 million malaria vaccine supply deal after three decades of research

GSK has secured its first supply contract for its malaria vaccine, thanks to more than 30 years of research and a half-decade of real world pilot studies (UNICEF).

Sun Pharma criticized by FDA for allegedly falsifying records and backdating documents in order to obtain drug samples

In a report on an inspection, USFDA claimed that Sun Pharmaceutical, one of the biggest suppliers of generic medications, had falsified a number of records managed to keep by employees at the Mohali plant.

DCGI approves AstraZeneca India to market breast cancer drug

Lynparza (Olaparib) has been approved by the Drugs Controller General of India (DCGI) as a monotherapy for the treatment of adult patients with early breast cancer who have previously received neoadjuvant or adjuvant chemotherapy.

Mankind Pharma and NOTTO collaborate on an organ donation awareness campaign

In collaboration with NOTTO (National Organ and Tissue Transplant Organization), Mankind Pharma recently held an organ donation awareness campaign and approximately 17,000 Mankind Pharma employees attended the live event and pledged to donate organs.

Intercept Pharma Resolves Patent Dispute With Dr. Reddy's Labs Regarding Generic Ocaliva

Intercept Pharmaceuticals Inc announced that it has reached a settlement agreement with Dr Reddy’s Laboratories to market a generic version of Ocaliva, which is used to treat a rare, chronic liver disease known as primary biliary cholangitis (PBC).

USFDA approved Bayer's Mirena LNG-releasing intrauterine system for contraception use

USFDA approved the supplemental New Drug Application (sNDA) for the extended use up to eight years in the indication, contraception, for Bayer’s levonorgestrel (LNG) releasing intrauterine system (IUS) Mirena.

Update profile

Please update your profile to keep using the website

Start chat
Need Help?
PharmaState Academy
Hello, how can we help you?